Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis
pharmafile | October 22, 2018 | News story | Research and Development, Sales and Marketing | Janssen, Tremfya, pharma, plaque psoriasis, psoriasis
Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin clearance which was maintained after three years of treatment.
Presented at the 37th Fall Clinical Dermatology Conference in Las Vegas, the data showed that 82.8% of Tremfya patients achieved and maintained a score of 90 on the Psoriasis Area Severity Index, representing a 90% improvement in skin clearance, while 96.4% of patients scored at least PASI 75.
Furthermore, 82.1% achieved an Investigator’s Global Assessment (IGA) score of 0 or 1 after 156 weeks of treatment. Of this figure, 50.8% scored 0.
Additionally, 40.2% of patients reported symptom scores of 0 on the Psoriasis Symptoms and Signs Diary (PSSD) after 100 weeks, representing a complete reduction in symptoms such as itching, pain, skin cracking or flaking, and bleeding. The number remained consistent after a third year, with 40.4% of patients reporting the same score.
“These findings are impressive as they demonstrate consistency in high rates of skin clearance with guselkumab treatment at Weeks 48, 100 and 156, with every eight-week maintenance therapy,” remarked Dr Andrew Blauvelt, President, Oregon Medical Research Center, and VOYAGE 1 study steering committee member. “In the management of moderate to severe plaque psoriasis, including symptom relief as well as skin clearance, it is essential that we continue to evaluate the impact of treatments with long-term data like those presented today. The VOYAGE 1 findings help further our understanding of the long-term impact of targeting IL-23 with guselkumab in the treatment of plaque psoriasis.”
Dr Newman Yeilding, Head of Immunology Development at Janssen Research & Development, also commented: “We are very pleased and excited by these results. The data adds to the growing body of safety and efficacy evidence with the use of guselkumab over a three-year period. As a part of our commitment to developing innovative therapies for chronic, immune-mediated diseases like psoriasis, we have been focusing on generating long-term data so that patients and physicians can be more informed when making treatment decisions.”
Matt Fellows
Related Content
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …